By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CardioDx today announced it has closed on a $60 million equity round.

The Palo Alto, Calif.-based cardiovascular genomics testing firm said that the funding will be used to expand reimbursement coverage in the US for its Corad CAD, a gene expression test to determine which patients have or don't have coronary artery disease. The test was launched in June 2009 as a laboratory-developed test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.